Masimo announces expanded partnership with Shenzhen Mindray for SET®
Category: #health  By Paroma Bhattacharya  Date: 2019-05-15
  • share
  • Twitter
  • Facebook
  • LinkedIn

Masimo announces expanded partnership with Shenzhen Mindray for SET®

With the invention of Signal Extraction Technology® (SET®), Masimo has established a new standard for pulse oximetry by presenting the ability to measure through motion and low perfusion.

The U.S. based medical device manufacturing company Masimo has reportedly announced that it has signed a purchase and license agreement with Shenzhen Mindray Bio-Medical Electronics Co., Ltd. to leverage Mindray’s SET® Measure-through Motion and Low Perfusion™ pulse oximetry – noninvasive, incessant measurement of oxygen saturation (SpO2), perfusion index (Pi), and pulse rate (PR),  – in monitoring devices.

Reportedly, the devices by Mindray which are equipped with SET® will be now available in select countries in the Middle East, Europe, the Commonwealth of Independent States, Asia-Pacific (excluding China), including Australia, India, and Russia.

With the invention of Signal Extraction Technology® (SET®), Masimo has established a new standard for pulse oximetry by presenting the ability to measure through motion and low perfusion. SET® has presented the highest sensitivity and specificity in detecting desaturation events and preventing false desaturation events during these conditions in a study which compared multiple pulse oximetry technologies.

SET® has reportedly launched latest frontiers in monitoring of patients during challenging conditions: outcome studies have shown that SET®, aided with clinical assessment, has facilitated clinicians to reduce retinopathy of prematurity (ROP) in neonates, improve critical congenital heart disease (CCHD) screening in infants, and reduce ICU transfers and rapid response team activations by continuously monitoring patients in post-surgical wards. Among all the studies, more than 100 independent and objective studies have demonstrated that SET® surpasses other pulse oximetry technologies. Masimo has continuously improved SET®, and recently announced that SpO2 precision specifications have now enhanced to 1.5 percent in conditions of motion and no motion for adult, pediatric, and newborn patients, weighing less than 3 kg, with RD SET™ sensors. 

The advantages of Masimo SET® are now available to clinicians leveraging devices of Mindray in several countries outside the U.S., where Mindray has provided SET® pulse oximetry in devices from Datascope since acquiring it in the year 2008.

Source credit: https://www.biospace.com/article/releases/masimo-and-mindray-announce-expanded-partnership/

http://www.masimo.com/company/news/news-media/#news-05b424de-a21b-4533-99c5-13f5ae2d3ed6



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

MacroGenics, I-Mab team up to develop & market enoblituzumab in China
MacroGenics, I-Mab team up to develop & market enoblituzumab in China
By Paroma Bhattacharya

MacroGenics, Inc. and I-Mab Biopharma, a U.S. and China based clinical-stage biopharmaceutical company that is committed to discover and develop biologics in autoimmune and immune-oncology diseases, have recently announc...

ViiV Healthcare announces positive result in TANGO Phase 3 study
ViiV Healthcare announces positive result in TANGO Phase 3 study
By Paroma Bhattacharya

ViiV Healthcare Limited, a pharmaceutical company specializing in HIV treatment, recently announced positive results from Phase 3 TANGO study.

The study was conducted to assess vira...

Skyhawk Therapeutics expands licensing partnership with Biogen
Skyhawk Therapeutics expands licensing partnership with Biogen
By Paroma Bhattacharya

Skyhawk Therapeutics, Inc. has recently announced the expansion of its partnership with Biogen, which was initially announced on January 4, 2019.

The expansion, which leverages on the breadth of SkySTAR™ technology platform from Skyh...